These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29172948)

  • 21. Kinetics of the antibody response to seasonal influenza vaccination among the elderly.
    Kositanont U; Assantachai P; Wasi C; Puthavathana P; Praditsuwan R
    Viral Immunol; 2012 Dec; 25(6):471-6. PubMed ID: 23061793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty.
    DiazGranados CA; Dunning AJ; Robertson CA; Talbot HK; Landolfi V; Greenberg DP
    Vaccine; 2015 Aug; 33(36):4565-71. PubMed ID: 26187260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults.
    Yao X; Hamilton RG; Weng NP; Xue QL; Bream JH; Li H; Tian J; Yeh SH; Resnick B; Xu X; Walston J; Fried LP; Leng SX
    Vaccine; 2011 Jul; 29(31):5015-21. PubMed ID: 21565245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.
    Kang EK; Eun BW; Kim NH; Lim JS; Lee JA; Kim DH
    BMC Infect Dis; 2016 Aug; 16(1):438. PubMed ID: 27549626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of prior influenza virus vaccination on maternal antibody responses: Implications for achieving protection in the newborns.
    Christian LM; Beverly C; Mitchell AM; Karlsson E; Porter K; Schultz-Cherry S; Ramilo O
    Vaccine; 2017 Sep; 35(39):5283-5290. PubMed ID: 28778612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
    Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
    Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?
    Skowronski DM; Tweed SA; De Serres G
    J Infect Dis; 2008 Feb; 197(4):490-502. PubMed ID: 18275271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
    Roggelin L; Vinnemeier CD; Meyer S; Witte K; Marx L; Theeß W; Burchard GD; Rolling T; Cramer JP
    Hum Vaccin Immunother; 2015; 11(10):2370-5. PubMed ID: 26114800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Stukova M; Buzitskaya Z; Кulmagambetov I; Davlyatshin T; Khairullin B
    Hum Vaccin Immunother; 2018 Mar; 14(3):609-614. PubMed ID: 29112488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of hemagglutination inhibition and microbead array assays for the measurement of influenza antibody levels in HIV-infected adults.
    Thorne A; Chowdhury F; Singer J; Keynan Y; Fowke KR; Cooper C;
    Vaccine; 2016 Jun; 34(31):3584-91. PubMed ID: 27211040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60-85 years old) and very elderly (>85 years old) institutionalized subjects.
    Nunzi E; Iorio AM; Camilloni B
    Hum Vaccin Immunother; 2017 Nov; 13(11):2659-2668. PubMed ID: 28922621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune response to influenza vaccination in community-dwelling Chinese elderly persons.
    Hui SL; Chu LW; Peiris JS; Chan KH; Chu D; Tsui W
    Vaccine; 2006 Jun; 24(25):5371-80. PubMed ID: 16713661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old.
    Keitel WA; Jackson LA; Edupuganti S; Winokur PL; Mulligan MJ; Thornburg NJ; Patel SM; Rouphael NG; Lai L; Bangaru S; McNeal MM; Bellamy AR; Hill HR;
    J Infect Dis; 2015 Aug; 212(4):552-61. PubMed ID: 25649171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of intradermal trivalent influenza vaccination in nursing home older adults: a randomized controlled trial.
    Chan TC; Hung IF; Chan KH; Li CP; Li PT; Luk JK; Chu LW; Chan FH
    J Am Med Dir Assoc; 2014 Aug; 15(8):607.e5-12. PubMed ID: 24957950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of influenza vaccine on tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in older adults.
    Keshtkar-Jahromi M; Ouyang M; Keshtkarjahromi M; Almed S; Li H; Walston JD; Rios R; Leng SX
    Vaccine; 2018 Apr; 36(16):2220-2225. PubMed ID: 29548604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose sparing with intradermal injection of influenza vaccine.
    Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
    N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
    Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.